Molecular pathways in renal cell carcinoma: Recent advances in genetics and molecular biology

Current Opinion in Oncology

Volumn 27, Issue 3, 2015, Pages 217-223

  Su, Daniel ^a   Singer, Eric A ^b   Srinivasan, Ramaprasad ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

molecular pathways; renal cell carcinoma; targeted therapy

Indexed keywords

CULLIN; CULLIN 3; ERYTHROID DERIVED 2 LIKE 2; FUMARATE HYDRATASE; HYPOXIA INDUCIBLE FACTOR; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; NUCLEAR FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; VASCULOTROPIN A;

ADVANCED CANCER; BAP1 GENE; CANCER GENETICS; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CITRIC ACID CYCLE; FAMILIAL CANCER; GENE SEQUENCE; GENOMICS; HUMAN; KIDNEY CARCINOMA; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; PBRM1 GENE; PRIORITY JOURNAL; REVIEW; SETD2 GENE; SYSTEMIC THERAPY; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; GENETICS; KIDNEY NEOPLASMS; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CARRIER PROTEINS; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84928486573     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000186     Document Type: Review

References (56)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65:5-29.
2. Singer EA, Gupta GN, Marchalik D, et al. Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol 2013; 25:273-280.
3. Keegan KA, Schupp CW, Chamie K, et al. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol 2012; 188:391-397.
4. Latif F, Tory K, Gnarra JR, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 28:1317-1320.
5. Moore LE, Nickerson ML, Brennan P, et al. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet 2011; 7:e1002312.
6. Linehan WM, Bratslavsky G, Pinto PA, et al. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med 2010; 61:329-343.
7. Johnson DG, Dent SY. Chromatin: receiver and quarterback for cellular signals. Cell 2013; 152:685-689.
8. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463:360-363.
9. Guo G, Gui Y, Gao S, et al. Frequent mutations of genes encoding ubiquitinmediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2012; 44:17-19.
10. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469:539-542.
11. Creighton CJ, Morgan M, Gunaratne PH, et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499:43-50.
12. Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 2013; 45:592-601.
13. Kapur P, Pen a-Llopis S, Christie A, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013; 14:159-167.
14. Edmunds JW, Mahadevan LC, Clayton AL. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J 2008; 27:406-420.
15. Li F, Mao G, Tong D, et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSa. Cell 2013; 153:590-600.
16. Dey A, Seshasayee D, Noubade R, et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 2012; 337:1541-1546.
17. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44:751-759.
18. Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet 2013; 92:974-980.
19. Joseph RW, Kapur P, Serie DJ, et al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer 2014; 120:1059-1067.
20. Gossage L, Murtaza M, Slatter AF, et al. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer 2014; 53:38-51.
21. Kapur P, Christie A, Raman JD, et al. BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. J Urol 2014; 191:603-610.
22. Hakimi AA, Ostrovnaya I, Reva B, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 2013; 19:3259-3267.
23. Ho TH, Kapur P, Joseph RW, et al. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. Urol Oncol Sem Orig Investig 2015; 33:.
24. Lager DJ, Huston BJ, Timmerman TG, et al. Papillary renal tumors. Morphologic, cytochemical, and genotypic features. Cancer 1995; 76:669-673.
25. Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2011; 2:1117-1133.
26. Steffens S, Janssen M, Roos FC, et al. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma: a multicentre study. Eur J Cancer 2012; 48:2347-2352.
27. Ronnen EA, Kondagunta GV, Ishill N, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 2006; 107:2617-2621.
28. Kroeger N, Xie W, Lee J-L, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013; 119:2999-3006.
29. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16:553-572.
30. Nakamura T, Sakai K, Nakamura T, et al. Hepatocyte growth factor twenty years on: much more than a growth factor. J Gastroenterol Hepatol 2011; 26 (Suppl 1):188-202.
31. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4:915-925.
32. Huh C-G, Factor VM, Sánchez A, et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 2004; 101:4477-4482.
33. Ma P, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metast Rev 2003; 22:309-325.
34. Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med 2005; 11:284-292.
35. Zhang Y-W, Vande Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 2003; 88:408-417.
36. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discovery 2005; 4:988-1004.
37. Boccaccio C, Ando M, Tamagnone L, et al. Induction of epithelial tubules by growth factorHGF depends ontheSTAT pathway.Nature1998;391:285-288.
38. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006; 103:2316-2321.
39. Lengyel E, Prechtel D, Resau JH, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005; 113:678-682.
40. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET protooncogene in papillary renal carcinomas. Oncogene 1999; 18:2343-2350.
41. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010; 7:277-285.
42. Adam J, Hatipoglu E, OFlaherty L, et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 2011; 20:524-537.
43. Kim JW, Tchernyshyov I, Semenza GL, et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3:177-185.
44. Kobayashi A, Kang M-I, Okawa H, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004; 24:7130-7139.
45. Bardella C, El-Bahrawy M, Frizzell N, et al. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol 2011; 225:4-11.
46. Kinch L, Grishin NV, Brugarolas J. Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell 2011; 20:418-420.
47. Ooi A, Dykema K, Ansari A, et al. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res 2013; 73:2044-2051.
48. Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011; 16:123-140.
49. DeNicola GM, Karreth FA, Humpton TJ, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011; 475:106-109.
50. Hanada N, Takahata T, Zhou Q, et al. Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer 2012; 12:66.
51. Zhang P, Singh A, Yegnasubramanian S, et al. Loss of Kelch-like ECHassociated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 2010; 9:336-346.
52. Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 2012; 12:564-571.
53. Soini Y,Eskelinen M, Juvonen P, et al.NuclearNrf2 expression is related to a poor survival in pancreatic adenocarcinoma. Pathol Res Pract 2014; 210:35-39.
54. Frezza C, Zheng L, Folger O, et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 2011; 477:225-228.
55. Na H-K, Surh Y-J. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radical Biol Med 2014; 67:353-365.
56. Sourbier C, Ricketts Christopher J, Matsumoto S, et al. Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer. Cancer Cell 2014; 26:840-850.